What the evidence actually supports
Evidence reviewed: 2026-11-16
Longevity peptides: no verified lifespan release
No controlled human lifespan-extension evidence was established for Epitalon, Pinealon, MOTS-c or SS-31 in this review. A laboratory telomere or mitochondrial signal is not evidence that a person lives longer or ages backwards. The only approval verified in this lane is elamipretide's, for a rare mitochondrial disease.
Track sleep, strength, activity and clinician-selected health measures without claiming a biological-age guarantee. Neither coaching nor favourable biomarker changes validates an experimental injectable or a self-directed cycle.
SS-31 / Elamipretide: one rare-disease approval
SS-31 is trending as a 'mitochondrial longevity' peptide. Its pharmaceutical form, elamipretide (Forzinity), received FDA accelerated approval on 19 September 2025 for one indication: improving muscle strength in Barth syndrome, a rare mitochondrial disease, in patients weighing at least 30 kg. The approval rested on knee-extensor strength in a 12-patient trial, and continued approval depends on confirmatory evidence.
That is evidence for a rare inherited disease, not for healthy ageing, energy or athletic output. A grey-market 'SS-31' vial is not Forzinity. Persistent fatigue deserves a medical work-up before anyone tells it a mitochondrial story.
MOTS-c
MOTS-c is a peptide encoded in mitochondrial DNA. Changhan Lee and colleagues in Pinchas Cohen's lab (Cell Metabolism, 2015) showed it acting on AMPK energy signalling and diet-induced obesity in mice. That is a strong mechanism with a thin human chapter: FDA's July 2026 briefing found human safety and effectiveness data insufficient, even though MOTS-c is in the October 2026 US compounding policy.
No validated human weight-loss or longevity regimen exists. Exercise is the best-studied way to recruit the same energy-sensing machinery, and it comes with a safety record.
Epitalon
Epitalon's telomerase and lifespan claims trace mainly to Vladimir Khavinson's group: animal, cell and small regional human reports. No controlled human lifespan or healthspan trial was identified in this review, and FDA's 2026 briefing found the safety evidence insufficient. Inclusion in the US compounding policy is an access decision.
A longer telomere on a lab report is not a longer life. Sleep timing, light exposure and treated sleep apnoea are the circadian levers with human outcome data.
GHK-Cu
Topical copper-peptide cosmetics and injectable GHK-Cu are different evidence questions. Limited topical studies do not establish systemic repair or lifespan extension. GHK-Cu was the fastest-rising peptide search of 2026, but injectable nominations were withdrawn and FDA says it will consult its compounding committee on non-injectable GHK-Cu before the end of February 2027.
Use cosmetic products according to their own instructions; do not extrapolate their results to injections. No validated injectable anti-ageing regimen. Skin symptoms still need dermatological assessment when persistent.
2026: easier US access is not new evidence
In April 2026 FDA took BPC-157, TB-500, Semax, Selank, MOTS-c, KPV, Epitalon, CJC-1295, AOD-9604, LL-37 and others off its Category 2 safety-risk list after their nominations were withdrawn. In July its compounding advisory committee narrowly recommended six of them for the 503A bulks list, over the objection of FDA's own drug reviewers, who found insufficient human safety and effectiveness evidence. On 30 October 2026 HHS published an interim policy: it will not act against US pharmacies compounding BPC-157, TB-500, MOTS-c, Epitalon, Semax or KPV if ten conditions are met.
That is an enforcement posture, not an FDA approval, a bulks-list rule or a clinical trial. It excludes 'research use only' vials and does not travel to Portugal, the UK or the EU, where a product presented or acting as a medicine still needs a marketing authorisation. Better sourcing lowers one risk, contamination, and leaves the efficacy question precisely where it was.